Family History of Primary Liver Cancer Associated with Increased Risk for Extrahepatic CCA

March 2022, Vol 3, No 1

The subtypes of cholangiocarcinoma (CCA), including intrahepatic CCA and extrahepatic CCA, have various underlying tumor microenvironments, pathobiology, epidemiologic features, and risk factors; however, the genetic underpinnings of the CCA subtypes have not been previously defined.

Madhulika Eluri, MD, University of Texas M.D. Anderson Hematology/Oncology Fellowship, Houston, and colleagues conducted a case-control study to determine the correlation between a family history of primary liver cancer and the incidence of CCA in the United States. Dr Eluri presented the results of the study at the 2022 ASCO GI Cancers Symposium.

This study was conducted at M.D. Anderson Cancer Center and included 429 patients with pathologically confirmed CCA and 1075 healthy controls. Of the 429 patients with CCA, 308 patients had intrahepatic CCA and 121 had extrahepatic CCA.

Patients were interviewed regarding their family history of cancer, including the number of relatives with cancer, the type of cancer, the patient’s relationship with the relative, and the age at which the relative was diagnosed with cancer.

Besides hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, having a family history of cancer was significantly associated with intrahepatic CCA (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.2-2.2) and extrahepatic CCA (OR, 1.6; 95% CI, 1.1-2.5). The prevalence of family history of primary liver cancer in first-degree members was higher in patients with extrahepatic CCA compared with patients with intrahepatic CCA (6.6% vs 1.6%, respectively). A higher proportion of patients in the extrahepatic CCA cohort had multiple relatives with primary liver cancer compared with the patients in the intrahepatic CCA cohort (4.1% vs 1%, respectively).

Although primary liver cancer in first-degree relatives was significantly associated with extrahepatic CCA (OR, 9.4; 95% CI, 2.9-30.7), no significant association was observed for patients with intrahepatic CCA (OR, 1.7; 95% CI, 0.5-5.9). All estimated ORs were adjusted for age, sex, race, smoking, alcohol, hepatitis virus infection, diabetes, and obesity.

The results of this case-control study indicate that having a family history of primary liver cancer in a first-degree family member is associated with an increased risk for extrahepatic CCA in the United States.

Source

Eluri M, Hatia R, Javle MM, Hassan M. The association of family history of primary liver cancer with cholangiocarcinoma: USA case-control study. Abstract 403.

Related Items

Tasurgratinib for Patients With FGFR2 Gene Fusion–Positive CCA: A Phase 2 Study
March 2024, Vol 5, No 1
Junji Furuse, MD, PhD, presented the results of a phase 2 study of tasurgratinib efficacy on patients with FGFR2 fusion-positive cholangiocarcinoma following gene fusion status confirmation by fluorescence in situ hybridization.
Safety and Efficacy of Telotristat Ethyl Plus First-Line Chemotherapy in Patients With Advanced BTC: A Phase 2, Open-Label Study
March 2024, Vol 5, No 1
Richard Kim, MD, presented the results of a phase 2, open-label study of patients who underwent telotristat ethyl plus first-line chemotherapy for the treatment of advanced biliary tract cancer.
Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials
March 2024, Vol 5, No 1
Teresa Macarulla, MD, PhD, presented the results of 2 phase 1a/1b dose-escalation/expansion trials, studies that measured the efficacy and safety of brigimadlin in patients with advanced biliary tract cancer.
COMPANION-002: A Phase 2/3 Randomized Study Design of CTX-009 Combination in Second-Line BTC
March 2024, Vol 5, No 1
A recombinant bispecific antibody, CTX-009, is discussed regarding its role in an ongoing phase 2/3 open-label, randomized, controlled study—a study being conducted to measure the efficacy of CTX-009 in previously treated, advanced, or metastatic biliary tract cancer.
A Phase 2 Clinical Trial of Anlotinib Plus TQB2450 (PD-L1 Blockade) Plus Nab-Paclitaxel and Cisplatin as First-Line Treatment for Advanced BTC
March 2024, Vol 5, No 1
Cholangiocarcinoma experts presented the preliminary results of a phase 2 clinical trial regarding anlotinib plus TQB2450, nab-paclitaxel, and cisplatin—a study conducted for the treatment of advanced biliary tract cancer.
Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC
March 2024, Vol 5, No 1
Zongli Zhang, MD, PhD, presented the preliminary results of an ongoing single-arm, multicenter, open-label, real-world study analyzing the efficacy and safety of surufatinib as a second-line treatment option for patients with biliary tract cancer.
Genomic Factors Indicating Sensitivity to IO and Chemotherapy in CCA
March 2024, Vol 5, No 1
Riya Jayesh Patel, MD, presented how the impact of transcriptomic signatures related to chemotherapy and immunotherapy sensitivity in the cholangiocarcinoma (CCA) cohort of The Cancer Genome Atlas could serve as evidence supporting the effectiveness of metabolism-targeted therapies in overcoming CCA therapeutic resistance.
Examining Real-World Testing, Treatment Patterns, and Outcomes After Liquid Biopsy in aCCA
March 2024, Vol 5, No 1
Amit Mahipal, MD, presented results from a real-world data study examining the rates of molecular alterations detected using circulating tumor DNA (ctDNA) for patients receiving ivosidenib following circulating tumor ctDNA-detected IDH1 mutations.
A Phase 2 Primary Analysis of Tislelizumab Plus Lenvatinib and GEMOX as Conversion Therapy in Potentially Resectable Locally Advanced BTC (ZSAB-TransGOLP)
March 2024, Vol 5, No 1
Jia Fan, PhD, presented results from a phase 2 trial that investigated the efficacy and safety of lenvatinib and a programmed cell death protein-1 antibody as conversion therapy for the treatment of potentially resectable and locally advanced biliary tract cancer.
Role of CD27 Agonist in Combination With PD-L1 and MEK Inhibition on Antitumor Effect and CD8+ T Cells: Expanding Immunotherapy Options in CCA
March 2024, Vol 5, No 1
Frances J. Bennett, MD, presented the results of a phase 2 trial that tested the antitumor effect of dual programmed death-ligand 1 plus mitogen-activated protein kinase inhibition in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: